Connection

Co-Authors

This is a "connection" page, showing publications co-authored by Diane Descamps and Yazdan Yazdanpanah.
Connection Strength

1.571
  1. Clinical and virological data of the first cases of COVID-19 in Europe: a case series. Lancet Infect Dis. 2020 06; 20(6):697-706.
    View in: PubMed
    Score: 0.218
  2. High rate of virologic suppression with raltegravir plus etravirine and darunavir/ritonavir among treatment-experienced patients infected with multidrug-resistant HIV: results of the ANRS 139 TRIO trial. Clin Infect Dis. 2009 Nov 01; 49(9):1441-9.
    View in: PubMed
    Score: 0.106
  3. Emergence of E484K Mutation Following Bamlanivimab Monotherapy among High-Risk Patients Infected with the Alpha Variant of SARS-CoV-2. Viruses. 2021 08 19; 13(8).
    View in: PubMed
    Score: 0.060
  4. Impact of the COVID-19 pandemic on the homeless: results from a retrospective closed cohort in France (March-May 2020). Clin Microbiol Infect. 2021 Oct; 27(10):1520.e1-1520.e5.
    View in: PubMed
    Score: 0.059
  5. Long-Term Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infectiousness Among Three Immunocompromised Patients: From Prolonged Viral Shedding to SARS-CoV-2 Superinfection. J Infect Dis. 2021 05 20; 223(9):1522-1527.
    View in: PubMed
    Score: 0.059
  6. High-risk exposure without personal protective equipment and infection with SARS-CoV-2 in-hospital workers - The CoV-CONTACT cohort. J Infect. 2021 05; 82(5):186-230.
    View in: PubMed
    Score: 0.058
  7. Outcome of SARS-CoV-2 infection is linked to MAIT cell activation and cytotoxicity. Nat Immunol. 2021 03; 22(3):322-335.
    View in: PubMed
    Score: 0.058
  8. Detection of SARS-CoV-2 N-antigen in blood during acute COVID-19 provides a sensitive new marker and new testing alternatives. Clin Microbiol Infect. 2020 12 08.
    View in: PubMed
    Score: 0.057
  9. Arterial Thrombotic Events in Adult Inpatients With COVID-19. Mayo Clin Proc. 2021 02; 96(2):295-303.
    View in: PubMed
    Score: 0.057
  10. A comparison of four serological assays for detecting anti-SARS-CoV-2 antibodies in human serum samples from different populations. Sci Transl Med. 2020 09 02; 12(559).
    View in: PubMed
    Score: 0.056
  11. Evaluation of the QIAstat-Dx Respiratory SARS-CoV-2 Panel, the First Rapid Multiplex PCR Commercial Assay for SARS-CoV-2 Detection. J Clin Microbiol. 2020 Jul 23; 58(8).
    View in: PubMed
    Score: 0.056
  12. Severe Acute Respiratory Syndrome Coronavirus 2-Specific Antibody Responses in Coronavirus Disease Patients. Emerg Infect Dis. 2020 Jul; 26(7):1478-1488.
    View in: PubMed
    Score: 0.056
  13. Challenges and issues about organizing a hospital to respond to the COVID-19 outbreak: experience from a French reference centre. Clin Microbiol Infect. 2020 Jun; 26(6):669-672.
    View in: PubMed
    Score: 0.055
  14. New mechanisms of resistance in virological failure to protease inhibitors: selection of non-described protease, Gag and Gp41 mutations. J Antimicrob Chemother. 2019 07 01; 74(7):2019-2023.
    View in: PubMed
    Score: 0.052
  15. Concentration-response model of rilpivirine in a cohort of HIV-1-infected naive and pre-treated patients. J Antimicrob Chemother. 2019 07 01; 74(7):1992-2002.
    View in: PubMed
    Score: 0.052
  16. HIV-1 protease, Gag and gp41 baseline substitutions associated with virological response to a PI-based regimen. J Antimicrob Chemother. 2019 06 01; 74(6):1679-1692.
    View in: PubMed
    Score: 0.052
  17. High virological suppression regardless of the genotypic susceptibility score after switching to a dolutegravir-based regimen: week 48 results in an observational cohort. J Antimicrob Chemother. 2018 06 01; 73(6):1665-1671.
    View in: PubMed
    Score: 0.048
  18. Serious neuropsychiatric adverse effects related to interaction between itraconazole and darunavir/ritonavir in an HIV-infected patient with cerebral histoplasmosis. J Antimicrob Chemother. 2018 04 01; 73(4):1108-1110.
    View in: PubMed
    Score: 0.048
  19. Population pharmacokinetics of Rilpivirine in HIV-1-infected patients treated with the single-tablet regimen rilpivirine/tenofovir/emtricitabine. Eur J Clin Pharmacol. 2018 Apr; 74(4):473-481.
    View in: PubMed
    Score: 0.047
  20. No impact of HIV-1 protease minority resistant variants on the virological response to a first-line PI-based regimen containing darunavir or atazanavir. J Antimicrob Chemother. 2018 Jan 01; 73(1):173-176.
    View in: PubMed
    Score: 0.047
  21. Prevalence of gag mutations associated with in vitro resistance to capsid inhibitor GS-CA1 in HIV-1 antiretroviral-naive patients. J Antimicrob Chemother. 2017 10 01; 72(10):2954-2955.
    View in: PubMed
    Score: 0.046
  22. Prevalence of respiratory viruses among adults, by season, age, respiratory tract region and type of medical unit in Paris, France, from 2011 to 2016. PLoS One. 2017; 12(7):e0180888.
    View in: PubMed
    Score: 0.045
  23. Switch as maintenance to elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate: week 48 results in a clinical cohort. J Antimicrob Chemother. 2017 06 01; 72(6):1745-1751.
    View in: PubMed
    Score: 0.045
  24. Disparities in HIV-1 transmitted drug resistance detected by ultradeep sequencing between men who have sex with men and heterosexual populations. HIV Med. 2017 10; 18(9):696-700.
    View in: PubMed
    Score: 0.045
  25. Impact of respiratory viruses in hospital-acquired pneumonia in the intensive care unit: A single-center retrospective study. J Clin Virol. 2017 06; 91:52-57.
    View in: PubMed
    Score: 0.045
  26. Impact of obesity on antiretroviral pharmacokinetics and immuno-virological response in HIV-infected patients: a case-control study. J Antimicrob Chemother. 2017 04 01; 72(4):1137-1146.
    View in: PubMed
    Score: 0.044
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.